Renaissance Capital logo

Xilio Therapeutics Priced, Nasdaq: XLO

Phase 1 biotech developing novel molecules to treat solid tumors.

Industry: Health Care

Latest Trade: $0.88 -0.06 (-6.5%)

First Day Return: 0.0%

Return from IPO: -94.1%

Industry: Health Care

We are a biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. We have built our geographically precise solutions, or GPS, platform to rapidly engineer novel molecules, including cytokines and other biologics, that are designed to optimize their therapeutic index by geographically localizing their activity inside tumors. Current immuno-oncology, or I-O, therapies have curative potential for patients with cancer; however, their potential is significantly curtailed by systemic toxicity that results from activity of the therapeutic molecule outside the tumor microenvironment, or TME. Our molecules are engineered to localize activity within the TME with minimal systemic effects, resulting in the potential to achieve enhanced anti-tumor activity. We are advancing a number of geographically precise, or tumor-selective, agents through various stages of development. Our most advanced product candidates are XTX101, an anti-cytotoxic T-lymphocyte-associated protein 4, or anti-CTLA-4, monoclonal antibody, or mAb, and XTX202, an interleukin 2, or IL-2, therapy. In June 2021, the U.S. Food and Drug Administration, or FDA, cleared our investigational new drug application, or IND, for XTX101, and we recently initiated our Phase 1 trial to evaluate XTX101 in patients with solid tumors.
more less
IPO Data
IPO File Date 10/01/2021
Offer Price $16.00
Price Range $16.00 - $18.00
Offer Shares (mm) 7.4
Deal Size ($mm) $118
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 10/21/2021
Offer Price $16.00
Price Range $16.00 - $18.00
Offer Shares (mm) 7.4
Deal Size ($mm) $118
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
Morgan Stanley
TD Cowen
more
Company Data
Headquarters Waltham, MA, United States
Founded 2015
Employees at IPO 64
Website www.xiliotx.com

Xilio Therapeutics (XLO) Performance